Genetic Characterization of Patients With Arrhythmia-Induced Cardiomyopathy
Understanding and Characterizing the Genetics of Patients With Arrhythmia-Induced Cardiomyopathy
Hospital Universitario 12 de Octubre
109 participants
Dec 1, 2024
OBSERVATIONAL
Conditions
Summary
The goal of this observational study is to learn about the genetic insights of arrhythmya-induced cardiomyopathy and its clinical prognosis. The main questions it aims to answer are: I. Does patients with arrhythmia-induced cardiomyopathy have a greater proportion of genetic mutations compared with other types of cardiomyopathy or general population? II. Have the genetics any prognostic impact in patients with arrhythmia-induced cardiomyopathy?
Eligibility
Inclusion Criteria4
- Presence of atrial fibrillation or atrial flutter not self-limited.
- Performance of a cardiac imaging test with systolic function analysis (echocardiogram, magnetic resonance, CT scan) during the clinical course of the arrhythmia, exhibiting a left ventricular ejection fraction (LVEF) \<50%. In order for the test to be representative, the maximum time between the performance of the imaging test and the rhythm control procedure will be 3 months, in the absence of intervening cardiovascular events that may have caused a variation in LVEF. In the event that the patient had a previously known LVEF \<50%, the change with respect to this attributable to tachyarrhythmia has to be ≥10%.
- Signature of informed consent.
- Ability to understand and accept participation in the study.
Exclusion Criteria14
- Refusal of informed consent.
- Legal or juridical incapacity.
- Age \<18 years.
- Life expectancy less than 1 year.
- Impossibility of a follow-up of at least 6 months.
- Presence of a ventricular rate \>140 beats per minute, limiting the validity of imaging measurements.
- Presence of known factors causing systolic ventricular dysfunction:
- Prior cardiomyopathy diagnosis.
- Severe mitral or aortic valve disease.
- Non-revascularizable ischemic heart disease.
- Context of peri-resuscitation cardiopulmonary care.
- Abusive alcohol consumption, defined as \>80 grams of ethanol or \>7 standard alcoholic beverages per day.
- Active treatment with chemotherapeutic agents or radiation therapy to the thorax.
- Known infection with Trypanosoma cruzi, Borrellia burgdorferi or other infectious agent causing cardiomyopathy.
Locations(4)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06896266